Biotechs Face Daunting Launch Environment Going It Alone

Q2 Updates From Biohaven, UroGen, Amarin And Others

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

Several small biotechs are launching new drugs independently in a launch environment that now presents unexpected challenges caused by COVID-19.

Woman Ascending Stairs
Biotechs launching alone face an even more challenging environment • Source: Shutterstock

An independent biotech launching a commercial drug on its own is always a big undertaking, but this year, several small biotechs are confronting new drug launches with the unexpected challenges of the COVID-19 health crisis. In reporting their second quarter earnings results, several of these drug makers highlighted how they are pushing ahead with new drug launches in a dynamic market.

Biotechs like Biohaven Pharmaceutical Holding Company Ltd., UroGen Pharma, Ltd., and bluebird bio are transitioning to commercial-stage...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.